Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Am J Hematol. 2021 Nov 24;97(2):194–202. doi: 10.1002/ajh.26410

FIGURE 2.

FIGURE 2

Human red blood cells (RBCs) survival in NOD scid gamma (NSG) mice. (A) Peripheral blood of NSG mice was collected before (upper panel) or after (lower panel) transfusion of human blood and subjected to flow cytometry analyses with anti-human CD235a antibody. (B) Human blood was transfused into naïve NSG mice or mice treated with cobra venom factor (CVF) only, clodronate liposomes (CL) only, or combination of CL and CVF. Peripheral blood was collected at different time points after transfusion and used for flow cytometry analyses. The percentages of circulating human CD235a+ RBCs were calculated. Data were from three independent experiments. (C) Flow cytometric dot plots on the peripheral blood of NSG mice treated with CL and CVF were presented from one of the three independent experiments